Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
-
Barr, Paul M. (University of Rochester)
;
Robak, Tadeusz (Medical University of Lodz) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ;
Bartlett, Nancy L. (Washington University School of Medicine) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Devereux, Stephen (Kings College Hospital) ;
Grosicki, Sebastian (School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Li, Jianyong (Jiangsu Province Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ;
Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ;
James, Danelle (Pharmacyclics. LLC an AbbVie Company) ;
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
